Nigel Theobald, CEO, N4 Pharma explores the future of targeted therapeutics with next-generation silica nanoparticle delivery.
In the evolving landscape of precision medicine and targeted therapy, success is increasingly determined not only by the efficacy of the drug itself, but also on the precision and reliability of the delivery mechanism employed. Targeted therapeutics, designed to interact with specific cellular pathways or disease sites, necessitate delivery systems that can evade the natural defences and barriers within the body to reach their intended targets without eliciting adverse effects.